Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer

In pre-treated K-ras wild-type status colorectal cancer, patients with high EREG gene expression appear to benefit more from cetuximab therapy compared with low expression. Epiregulin as a selective biomarker requires further evaluation.